What are Robert Blum’s direct CYTK share holdings after these transactions?

After the reported option exercise, Robert Blum held 164,245 shares of CYTOKINETICS common stock directly. This figure is reported as his total direct holdings following the derivative transaction.

Cytokinetics CEO sells 7,500 shares at $70.24

Q: What did CYTK President & CEO Robert Blum report on this Form 4 for CYTK?

He exercised 7,500 options at $10.60 per share into 7,500 CYTOKINETICS common shares and sold 7,500 shares at $70.24 per share, in transactions made under a Rule 10b5-1 trading plan.

Q: How many CYTK shares did Robert Blum sell and at what price?

Robert Blum sold 7,500 shares of CYTOKINETICS common stock at a price of $70.24 per share on August 31, 2026, as reported on this Form 4.

Q: What options did Robert Blum exercise in CYTK stock?

He exercised a Non-Qualified Stock Option for 7,500 shares of CYTOKINETICS common stock at an exercise price of $10.60 per share. The option was originally exercisable from March 28, 2017 and expires on February 28, 2027.

Q: What indirect CYTK holdings does Robert Blum report through trusts?

He reports indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, as noted in the Form 4 footnotes.

CYTOKINETICS INC (CYTK) reported that President & CEO Robert I. Blum exercised options and sold shares in a coordinated transaction under a Rule 10b5-1 trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) reported that President & CEO Robert I. Blum exercised options and sold shares in a coordinated transaction under a Rule 10b5-1 trading plan. He exercised 7,500 Non-Qualified Stock Options at an exercise price of $10.60 per share, receiving 7,500 common shares, and on the same date sold 7,500 common shares at $70.24 per share. Following the option exercise, he held 164,245 shares of common stock directly, plus indirect holdings of 2,083 shares in each of two irrevocable trusts.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($447K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($527K)

Approx. gross sale proceeds $527K

Approx. exercise cost $80K

Approx. pre-tax spread $447K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.60	$80K
Sale	Common Stock	7,500	$70.24	$527K
holding	Common Stock ^F1	--	--	--
holding	Common Stock ^F2	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 164,245 contracts (Direct); Common Stock — 377,820 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1); Common Stock — 2,083 shares (Indirect, by Trust 2)

Footnotes (2)

F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Options exercised: 7,500 shares Option exercise price: $10.60 per share Shares sold: 7,500 shares +4 more

7 metrics

Options exercised 7,500 shares Non-Qualified Stock Option (Right to Buy) exercised on August 31, 2026

Option exercise price $10.60 per share Exercise price of Non-Qualified Stock Option for 7,500 shares

Shares sold 7,500 shares Common Stock sale on August 31, 2026

Sale price $70.24 per share Price for 7,500 CYTOKINETICS common shares sold

Direct holdings after exercise 164,245 shares Total common stock directly owned by Robert Blum after derivative transaction

Indirect holdings by Trust 1 2,083 shares Common Stock held by The Bridget Blum 2003 Irrevocable Trust

Indirect holdings by Trust 2 2,083 shares Common Stock held by The Brittany Blum 2003 Irrevocable Trust

Key Terms

Non-Qualified Stock Option (Right to Buy), Irrevocable Trust, indirect ownership

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: Non-Qualified Stock Option (Right to Buy)"

Irrevocable Trust financial

"Shares held by The Bridget Blum 2003 Irrevocable Trust."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

indirect ownership financial

"ownership_type: indirect, nature_of_ownership: by Trust 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CYTK President & CEO Robert Blum report on this Form 4 for CYTK?

He exercised 7,500 options at $10.60 per share into 7,500 CYTOKINETICS common shares and sold 7,500 shares at $70.24 per share, in transactions made under a Rule 10b5-1 trading plan.

How many CYTK shares did Robert Blum sell and at what price?

Robert Blum sold 7,500 shares of CYTOKINETICS common stock at a price of $70.24 per share on August 31, 2026, as reported on this Form 4.

What options did Robert Blum exercise in CYTK stock?

He exercised a Non-Qualified Stock Option for 7,500 shares of CYTOKINETICS common stock at an exercise price of $10.60 per share. The option was originally exercisable from March 28, 2017 and expires on February 28, 2027.

What indirect CYTK holdings does Robert Blum report through trusts?

He reports indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, as noted in the Form 4 footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 04:56 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:55 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/31/2026		M		7,500	A	$10.6	385,320	D
Common Stock	08/31/2026		S		7,500	D	$70.24	377,820	D
Common Stock								2,083	I	by Trust 1⁽¹⁾
Common Stock								2,083	I	by Trust 2⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$10.6	08/31/2026		M			7,500	03/28/2017	02/28/2027	Common Stock	7,500	$0	164,245	D

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR